Press Releases Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
42.05 ^USD	-0.12%		-0.02%	-0.83%

May. 14	Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing	MT
May. 08	Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NOTICE OF INVESTIGATION: Kaskela Law LLC Announces Shareholder Investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and Encourages Investors to Contact the Firm	May. 20	PR
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease	Apr. 19	AQ
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease	Apr. 18	AQ
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders	Jan. 08	BU
CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE	Dec. 08	BU
AbbVie to buy neuroscience specialist Cerevel Therapeutics for $8.7bn	Dec. 08	AQ
JetBlue Airways, Semtech rise; Duckhorn, Chewy fall, Thursday, 12/7/2023	Dec. 07	AQ
Shareholder Alert: Ademi LLP investigates whether Cerevel Therapeutics has obtained a Fair Price in its transaction with AbbVie	Dec. 06	PR
CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel Therapeutics	Dec. 06	PR
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders	Dec. 06	BU
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline	Dec. 06	PR
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease	Nov. 29	AQ
Cerevel Therapeutics to Present at Upcoming Investor Conferences	Nov. 08	AQ
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates	Nov. 01	AQ
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023	23-10-13	AQ
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock	23-10-11	AQ
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock	23-10-11	AQ
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference	23-08-29	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE	23-08-18	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE	23-08-10	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Press Releases

Filters